Boardroom Alpha
Boardroom Alpha
SRZN · Current Report (Form 8-K) · Filed May 14, 2026

Surrozen Inc — Current Report (Form 8-K)

Form
8-K
Filed
May 14, 2026
Period
May 13, 2026
Ticker
SRZN
Accession
0001193125-26-224037
Boardroom Alpha · Filing insights

Two Class II directors elected; EY LLP ratified; executive pay advisory approved; annual frequency set.

About Surrozen Inc
Market cap
$269M
1Y TSR
+219.5%
3Y TSR
+44.3%
Board grade
C
Sector
Healthcare
CEO
Craig C Parker
Last annual meeting: May 13, 2026 · View full Surrozen Inc profile →
8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 13, 2026

 

 

Surrozen, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39635

30-1374889

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

171 Oyster Point Blvd

Suite 400

 

South San Francisco, California

 

94080

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (650) 489-9000

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

SRZN

 

The Nasdaq Capital Market

Redeemable warrants, each whole warrant exercisable for one-fifteenth of a share of Common Stock

 

SRZNW

 

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 13, 2026, Surrozen, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (“Annual Meeting”). A total of 11,486,707 shares of the Company’s common stock were entitled to vote as of March 18, 2026, the record date for the Annual Meeting, of which 7,744,669 shares were represented in person or by proxy at the Annual Meeting. Proxies for the Annual Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition of management’s solicitation.

At the Annual Meeting, the stockholders of the Company voted on the following proposals:

1.
the election of two nominees, each to serve as a Class II director of the Company until the 2029 Annual Meeting of Stockholders or until the election and qualification of his or her successor, subject to his or her earlier death, resignation or removal; and
2.
the ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.
3.
the approval, on an advisory basis, of the compensation of the Company’s named executive officers.
4.
the advisory vote on the preferred frequency of the advisory vote on the compensation of the Company’s named executive officers.

The results of each of the above proposals are discussed further below.

Proposal 1 – Election of Directors

The votes cast for or withheld for each director nominee, and the number of broker non-votes, were as follows:

Director Nominee

 

For

 

Withheld

 

Broker Non-Votes

Mace Rothenberg, M.D.

 

 5,982,651

 

 1,107,751

 

 654,267

David J. Woodhouse, Ph.D.

 

 7,087,293

 

 3,109

 

 654,267

Accordingly, the two nominees listed above were each elected to serve as a Class II director of the Company until the 2029 Annual Meeting of Stockholders or until the election and qualification of his or her successor, subject to his or her earlier death, resignation or removal.

Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm

The voting results with respect to the proposal to ratify the appointment of Ernst & Young LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2026 were as follows:

For

 

Against

 

Abstain

 7,744,358

 

 284

 

27

 

Accordingly, the Company’s stockholders ratified the appointment of Ernst & Young LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2026.

Proposal 3 – Advisory Vote on Executive Compensation

The Company’s stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K compensation tables and narrative discussions, by the following votes:

For

 

Against

 

Abstain

 

Broker Non-Votes

 6,312,815

 

 776,738

 

 849

 

 654,267

 


Proposal 4 – Advisory Vote on the Preferred Frequency of Advisory Approval of Executive Compensation

The Company’s stockholders approved, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company’s named executive officers, by the following votes:

1 Year

 

2 Years

 

3 Years

 

Abstain

 

Broker Non-Votes

7,068,763

 

0

 

21,636

 

3

 

 654,267

 

In accordance with the recommendation of the Company’s board of directors and based on the results of the advisory vote reported above, the Company has determined that it will hold future advisory votes on the compensation of the Company’s named executive officers on an annual basis until the next required advisory vote on the frequency of stockholder advisory vote on the compensation of the Company’s named executive officers.

 

No other matters were submitted to a vote of the stockholders at the Annual Meeting.

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

SURROZEN, INC.

 

 

 

 

Date:

May 14, 2026

By:

/s/ Charles Williams

 

 

 

Name: Charles Williams
Title: Chief Operating Officer and Corporate Secretary

 


From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Surrozen Inc (SRZN)

Reference

Frequently asked questions

When did Surrozen Inc file this 8-K?
Surrozen Inc (SRZN) filed this Current Report (Form 8-K) with the SEC on May 14, 2026. The accession number assigned by EDGAR is 0001193125-26-224037.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Two Class II directors elected; EY LLP ratified; executive pay advisory approved; annual frequency set. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Surrozen Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Surrozen Inc has filed under CIK 1824893, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer